Showing results (201-210 of 219) with videos related to
Sort By:
Pageof 22
Immunogenetics|October 8, 2003
Genomic analysis of immunity in a Urochordate and the emergence of the vertebrate immune system: "waiting for Godot"Kaoru Azumi, Rosaria De Santis, Anthony De Tomaso, et al.International Journal of Antimicrobial Agents|July 10, 2023
Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trialShu Okugawa, Mahoko Ikeda, Kosuke Kashiwabara, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 StudyAditya Bardia, Ian E Krop, Takahiro Kogawa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.Cancer Research Communications|July 12, 2023
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase IbHanae Ida, Toshio Shimizu, Makoto Nishino, et al.International Journal of Clinical Oncology|November 26, 2025
Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypesKazuhiro Ko, Mayu Fukuda, Koji Yamanoi, et al.European Journal of Cancer (Oxford, England : 1990)|July 6, 2026
Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphomaElena Garralda, Patrick Schöffski, Arjun Oberoi, et al.The Oncologist|April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspectiveMerel J J Lucassen, Pedro Bergmann, Olga Husson, et al.Journal of the Neurological Sciences|July 18, 2016
Japanese version of the ALS-FTD-Questionnaire (ALS-FTD-Q-J)Yasuhiro Watanabe, Emma Beeldman, Joost Raaphorst, et al.Journal of Neurology|January 20, 2020
Cognitive and behavioral status in Japanese ALS patients: a multicenter studyYasuhiro Watanabe, Joost Raaphorst, Yuishin Izumi, et al.Pageof 22